NeurogastrxNG101的NG101药物在第二阶段试验中,将微硫化物使用者中的恶心和呕吐减少70%。 Neurogastrx's NG101 drug reduced nausea and vomiting in semaglutide users by up to 70% in a Phase 2 trial.

Neurogastrx报告说,NG101试验阶段2取得了积极成果,这是一种口服药物,大大减少了服用甘油的人的恶心和呕吐,一种常见的GLP-1肥胖和糖尿病药物。 Neurogastrx reported positive Phase 2 trial results for NG101, an oral drug that significantly reduced nausea and vomiting in people taking semaglutide, a common GLP-1 medication for obesity and diabetes. 在对90名成年人进行的一项研究中,NG101将恶心减少40%,呕吐67%,与安慰剂相比,症状严重程度减少70%,副作用减少。 In a study of 90 adults, NG101 cut nausea by 40%, vomiting by 67%, and reduced symptom severity by 70% compared to placebo, with fewer side effects. 这种药物针对恶心,但不影响大脑食欲控制中心,可以帮助病人在有效治疗中停留更长的时间。 The drug, which targets nausea without affecting the brain’s appetite control center, may help patients stay on effective treatments longer. 在2025年ObesityWeek会议上介绍了结果,该公司还任命了一名新的首席执行官,以推进发展。 Results were presented at ObesityWeek 2025, and the company also named a new CEO as it advances development.